Clinical context A 23-year-old man with a first episode of psychosis has been on low-dose oral haloperidol for
1 week. Auditory hallucinations and persecutory delusions remain strong. The question asks how often follow-up contact should occur at this stage under the WHO mhGAP-IG framework.
Why the answer is “as often as possible, even daily” In early psychosis treatment, the first
2–4 weeks after starting an antipsychotic are the highest-risk period for non-response, distressing symptoms, poor adherence, and safety concerns such as agitation or self-harm. The mhGAP-IG therefore recommends that initial follow-up be
as frequent as possible, even daily, until acute symptoms respond to treatment. The goal is not simply to wait for the medication’s full effect, but to actively monitor symptom intensity, tolerability, and the person’s safety during the acute phase.
Haloperidol, a first-generation antipsychotic, has a relatively rapid onset for agitation and positive symptoms, but full antipsychotic response may take
2–6 weeks. During that window, the nurse’s frequent contact serves several purposes: confirming the person is taking the medication, checking for extrapyramidal side effects such as acute dystonia or akathisia, assessing whether hallucinations or delusions are worsening, and providing psychosocial support.
Key point! In mhGAP-IG, follow-up frequency is tied to clinical stage, not to a fixed calendar schedule. Acute, unresponsive symptoms justify daily contact; stable, responding symptoms allow spacing to monthly or quarterly.
| Clinical stage | Recommended follow-up frequency | Rationale |
|---|
| Acute psychosis, symptoms still strong after starting antipsychotic | As often as possible, even daily | Monitor response, safety, adherence, and side effects during the highest-risk period |
| Symptoms begin to respond | Weekly to every 2 weeks | Confirm sustained improvement and adjust dose if needed |
| Stable or recovered | Monthly to every 3 months | Maintain remission, monitor relapse signs, ensure medication supply |
Why the other options are incorrect Option 2,
every 2 weeks, is too infrequent for a person whose voices and fears are still strong after only
1 week of treatment. Option 3,
once a month, and option 4,
every 3 months, are appropriate only after the acute symptoms have responded and the person is clinically stable.
Watch out! Do not confuse “full effect of the medicine” with “acute symptom response.” mhGAP-IG does not wait for the full therapeutic effect before intensifying follow-up; it intensifies follow-up precisely because the full effect has not yet occurred.
Rural Health Unit context In a resource-limited RHU setting, daily contact may be achieved through a combination of clinic visits, home visits by a community health worker, or telephone follow-up. The mhGAP-IG is designed for non-specialist primary care providers, so the nurse’s role includes both clinical monitoring and coordination with family members or community supports.
Frequent early contact is a safety intervention, not just a scheduling preference, because it allows early detection of non-response, intolerable side effects, or emerging risk before a crisis develops.
Integration with the evidence base The mhGAP-IG approach aligns with real-world recommendations for early psychosis care that emphasize assertive, stage-matched follow-up in the initial treatment phase . Implementation studies of mhGAP-IG in rural primary care settings confirm that non-specialist workers can deliver this structured follow-up model when trained and supported, and that the acute phase requires the most intensive contact . The principle is consistent:
follow-up intensity should match clinical acuity, with the highest frequency reserved for the period before symptom response is established.